WZ,
I think that your position is legitimate (even if far from mine) but I have some points to raise to your attention:
I believe that whoever is discussing for a partnership with IPCI has probably the resource, knowledge and skills to assess any possible issues, blue dye included.
If an Agreement is made, looking at the kind of Agreement signed and from how it is structured you will have a good approximation of how it is going to end.
" But I look for long term fundamentals, and those are weak here. No public HAL studies for Rexista says all I need to know. With Rexista unlikely to get approval with current formulation, there is nothing for PODRAS to enhance, even if future IPCI engineers can get it to work."
worst scenario I see is they remove the dye. I don't think it's going to happen; but it will be a delay at max. So on the contrary to what you say: long term your likely to emerge as the best in class
"Generics are a joke- still waiting to hear about Focalin from their partner that no longer exists. Keppra languishes. Most pending ANDA's are late to well-established markets."
They are marginal, not a joke; a joke is FDA approval process. ANDAs can turn this tiny company very profitable (in relation to its size)
Catalysts for this company tend to be rumors on twitter. Not my kind of investment.
You know it's not true. We had 1 rumor in 3 yrs...and catalyst are in the pipeline and in the partnership discussions. This last of yours is just nonsense and I understood you are much much better than this.
